merlano marco carlo - Azienda Ospedaliera S. Croce e Carle

Transcript

CURRICULUM VITAE
INFORMAZIONI PERSONALI
Cognome e Nome
MERLANO MARCO CARLO
Indirizzo istituzionale
VIA M. COPPINO 26
Telefono istituzionale
0171616739
E-mail istituzionale
Amministrazione
Qualifica
Incarico Aziendale
[email protected]
AZIENDA OSPEDALIERA S.CROCE E CARLE CUNEO
MEDICO
DIRETTORE ONCOLOGIA
FORMAZIONE ED ESPERIENZA
LAVORATIVA
TITOLI DI STUDIO
Specializzazione in oncologia (1981)
Presso Università degli studi di Genova
Con votazione 50/50L
Laurea in medicina e chirurgia (1978)
Presso Università degli studi di Genova
Con votazione 107/110
ESPERIENZA LAVORATIVA
Incarico di Direttore di dipartimento
Presso AO S.Croce & Carle Cuneo
Dal 2001 al presente
Incarico di Direttore Oncologia
Presso AO S.Croce & Carle Cuneo
Dal 1997 al presente
Incarico di aiuto responsabile modulo degenze protette
Presso Istituto Nazionale per la Ricerca sul Cancro, Genova
(1995 – 1997)
Incarico di aiuto
Presso Istituto Nazionale per la Ricerca sul Cancro, Genova
(1990 – 1995)
Incarico di assistente
Istituto Nazionale per la Ricerca sul Cancro, Genova
(1980 – 1990)
ISTRUZIONE E FORMAZIONE
Training formativo c/o Sidney Farber Cancer Institute, Harvard Medical School, Boston, MA,
USA
(giugno/luglio 1980)
Training formativo c/o Radiobiology and Byophysic unit, University of Virginia in Charlottesvile,
VI, USA (Marzo/Aprile 1988)
Guest Resercher c/o Medical Oncology Dept, Rush Presbyterian School of Medicine, Chicago,
IL, USA
(Gennaio/febbraio 1989)
CAPACITÀ E COMPETENZE
PERSONALI
MADRELINGUA
Pagina 1 -
ITALIANA
Curriculum vitae di Merlano Marco
ALTRE LINGUA
Pagina 2 -
LINGUA
Livello parlato
Livello scritto
INGLESE
BUONO
BUONO
AUTORE O CO-AUTORE DI CIRCA 150 ARTICOLI SU RIVISTE SCIENTIFICHE INDICIZZATE E PEER REVIEWED
(SEGUE UNA SELEZIONE DEGLI ARTICOLI DEGLI ULTIMI 5 ANNI)
PUBBLICAZIONI
A2015 – Articolo su rivista
Panzuto F, Rinzivillo M, Fazio N… Merlano M… Delel Fave G
Real-world study of everolimus in advanced progressive neuroendocrine
tumors
(2015) Oncologist 20(5):570
Source: PubMed
2015 – articolo su rivista
Tonissi F, Lattanzio L, Merlano MC, Infante L, Lo Nigro C, Garrone O
The effect of paclitaxel and nab-paclitaxel in combination with antiangiogenic therapy in breast cancer cell lines
(2015) Invest New Drugs May / (epub ahead of print)
Source: PubMed
Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D,
Tonissi F, Merlano M, Lo Nigro C
The relevance of ADCC for EGFR targeting: A review of the literature and
a clinically-applicable method of assessment in patients.
(2015) Critical Rev Oncol Hematol 10.1016/j.critrevonc.2015.02.014
Source: PubMed
Mirabile A, Numico G, Russi EG… Merlano MC… Dellinger RP
Sepsis in head and neck cancer patients trweated with chemotherapy
and radioation: Literature review and consensus
(2015) Critical Rev Oncol Hematol
doi:10.1016/j.critrevonc.2015.03.003
Source: PubMed
2015 – Articolo su rivista
Garrone O, Bertelli G, Principe E, Lewis PD, Occelli M, Miraglio E, Merlano
MC
A prospective randomized study of transvaginal ultrasound effects of
tamoxifen and exemestane in postmenopausal women with early breast
cancer.
(2014) Tumori 100(6):620-4
Source: PubMed
Lattanzio L, Tonissi F, Monteverde M, Vivenza D, Russi EG, Milano G,
Merlano M, Lo Nigrop C.
Treatment effect of buparlisib, cetuximab, and irradiation in wild-type or
PI3KCA-mutated head and neck cancer lines.
(2015) Invest New Drugs 33(2):310-20
Source: PubMed
Mesia R, Henke M, Fortin A…Merlano MC… Girault J.
Chemoradiotherapy with or without panitumumab in patients with
unresected, locally advanced squamous cell carcinoma of the head and
neck (CONCERT-1): a randomized, controlled, open-label phase II trial
(2015) Lancet Oncol 33(2):208-20
Source: PubMed
Lattanzio L, Borgognone M, Mocellini C, Giordano F, … Merlano MC, Lo
Nigro C.
MGMT promoter methylation and glioblastoma: a comparison of
analytical methods and of tumor specimens.
(2015) Int J Biol Markers 30(2):e208-16
Source: PubMed
Pagina 3 -
Denaro N, Merlano MC, Russi EG, Lo Nigro C
Non Coding RNAs in head and neck squamous cell carcinoma (HNSCC):
a clinical perspective.
(2014) Anticancer Res 34(12):68867-96
Source: PubMed
Panzuto F, Rinzivillo M, Fazio N… Merlano MC…Delle Fave G
Real-world study of everolimus in advanced progressive neuroendocrine
tumors.
(2014) Oncologist 19(9):966-974
Source: PubMed
Denaro N, Russi EG, Adamop V, Merlano MC
State-of the-art and emerging treatment options in the management of
head and neck cancer: news from 2013.
(2014) Oncology 86(4):212-229
Source: PubMed
Messa F, Tonissi F, Millo E, Bracco E, Ungari S, Lattanzio L, Merlano M,
Damonte G, Lo Nigro C
A PNA-Mediated clamping PCR for routine detection of Kras mutations in
colorectal carcinoma.
(2014) Int. J Biol Markers 29(1):e55-61
Source: PubMed
Denaro N, Nigro CL, Russi EG, Merlano MC
The role of chemotherapy and latest emerging target therapies in
anaplastic thyroid cancer
(2013) Onco Targets Ther 16(9):1231-1241
Source: PubMed
Denaro N, Russi EG, Merlano MC
Strategies for non-resectable head and neck cancer
(2013) Curr Treat Options Oncol. 14(4):492-504
Source: PubMed
Vivenza D, Feola M, Garrone O, Monteverde M, Merlano MC, Lo Nigro C.
Role of Renin-angiotensin-aldosterone system and the glutathioneStransferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after
anthracycline chemotherapy for breast carcinoma.
(2013) Int. J. Biol. Markers 28(4):e336-47
Source: PubMed
2013 – lettera su rivista
Russi EG, Numico G, Merlano MC
Non-surgical conservative approach for laringea cancer: what
information should patients be given?
(2013) J. Clin. Oncol. 31(25):3168-70
Source: PubMed
Guérin, O., Etienne-Grimaldi, M.-C., Monteverde, M., Sudaka, A.,
Brunstein, M.-C., Formento, P., Lattanzio, L., Maffi, M., Tonissi, F.,
Ortholan, C., Pagès, G., Fischel, J.-L., Lo Nigro, C., Merlano, M., Milano,
G.
Contrasted effects of the multitarget TKi vandetanib on docetaxelsensitive and docetaxel-resistant prostate cancer cell lines
Pagina 4 -
(2013) Urologic Oncology: Seminars and Original Investigations, 31
(8), pp. 1567-1575.
Document Type: Article
Source: Scopus
Impact Factor (I.F.) 3.647
Denaro, N., Russi, E.G., Lefebvre, J.L., Merlano, M.C.
A systematic review of current and emerging approaches in the field of
larynx preservation
(2014) Radiotherapy and Oncology, . Article in Press.
Document Type: Article in Press
Source: Scopus
I.F. 4.520
Lattanzio, L., Tonissi, F., Torta, I., Gianello, L., Russi, E., Milano, G.,
Merlano, M., Lo Nigro, C.
Role of IL-8 induced angiogenesis in uveal melanoma
(2013) Investigational New Drugs, 31 (5), pp. 1107-1114.
Source: Scopus
I.F. 3.498
Russi, E.G., Bensadoun, R.-J., Merlano, M.C., Bourhis, J., Ricardi, U.,
Giralt, J., Pinto, C., Budach, W., Corvò, R., Lacouture, M.E., Bernier, J.
Bio-radiation dermatitis: The need of a new grading: In regard to
Bernier et al: Ann Oncol 2011; 22 (10): 2191-2200
(2013) Annals of Oncology, 24 (9), art. no. mdt281, pp. 2463-2465.
Document Type: Letter
Source: Scopus
I.F. 7.384
Denaro, N., Merlano, M.C., Russi, E.G.
Dysphagia in head and neck cancer patients: Pretreatment evaluation,
predictive factors, and assessment during radio-chemotherapy,
recommendations
(2013) Clinical and Experimental Otorhinolaryngology, 6 (3), pp.
117-126.
Document Type: Review
Source: Scopus
I.F. 1.13
Monteverde, M., Tonissi, F., Fischel, J.-L., Etienne-Grimaldi, M.-C.,
Milano, G., Merlano, M., Lo Nigro, C.
Combination of docetaxel and vandetanib in docetaxel-sensitive or
resistant PC3 cell line
(2013) Urologic Oncology: Seminars and Original Investigations,
31 (6), pp. 776-786.
Source: Scopus
I.F. 3.647
Nigro, C.L., Wang, H., McHugh, A., Lattanzio, L., Matin, R., Harwood, C.,
Syed, N., Hatzimichael, E., Briasoulis, E., Merlano, M., Evans, A.,
Thompson, A., Leigh, I., Fleming, C., Inman, G.J., Proby, C., Crook, T.
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a
biomarker of metastatic melanoma
(2013) Journal of Investigative Dermatology, 133 (5), pp. 12781285. Cited 2 times.
Pagina 5 -
Source: Scopus
I.F. 6.193
2013 - articolo su rivista
Lattanzio, L., Tonissi, F., Monteverde, M., Milano, G., Merlano, M.C., Lo
Nigro, C.
Differential molecular mechanism of docetaxel-octreotide combined
treatment according to the docetaxel resistance status in PC3 prostate
cancer cells
(2013) Anti-Cancer Drugs, 24 (2), pp. 120-130.
Source: Scopus
I.F. 2.232
Sudaka, A., Susini, A., Lo Nigro, C., Fischel, J.-L., Toussan, N.,
Formento, P., Tonissi, F., Lattanzio, L., Russi, E., Etienne-Grimaldi, M.C.,
Merlano, M., Milano, G.
Combination of bevacizumab and irradiation on uveal melanoma: An in
vitro and in vivo preclinical study
(2013) Investigational New Drugs, 31 (1), pp. 59-65. Cited 1 time.
Source: Scopus
I.F. 3.498
2013 – Articolo in rivista
Denaro, N., Russi, E.G., Numico, G., Pazzaia, T., Vitiello, R., Merlano,
M.C.
The role of neck dissection after radical chemoradiation for locally
advanced head and neck cancer: Should we move back?
(2013) Oncology (Switzerland), 84 (3), pp. 174-185.
Source: Scopus
I.F. 2.112
2012 - Articolo in rivista
Palmieri c, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N,
LoNigro C, Merlano M, Crook T (2012).
Site-specific CpG Methylation in the CCAAT/enhancer binding protein delta
(CEBP)CpG island in breast cancer is associated with metastatic relapse.
BRITISH JOURNAL OF CANCER,
ISSN: 0007-0920
Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O,
LoNigro C, Merlano M, Crook T (2012).
Methylation of the calcium channel regulatory subunit A2D-3 (CACNA2D3) predicts
site-specific relapse in oestrogen receptor-positive primary breast carcinomas.
BRITISH JOURNAL OF CANCER, ISSN: 0007-0920
Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N,
Merlano M, LoNigro C (2012).
MDM 309 polymorphism predicts outcome in platinum-treated locally advanced
head and
neck cancer.
ORAL ONCOLOGY, ISSN: 1368-8375
Denaro N, Russi EG, Colantonio I, Adamo V, Merlano M (2012).
The role of antiangiogenic agents in the treatment of head and neck cancer.
ONCOLOGY, ISSN: 0030-2414
LoNigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N,
Garrone O, Merlano M, Crook T (2012).
Pagina 6 -
NT5E CpG island methylation is a fovourable breast cancer biomarker. BRITISH
JOURNAL OF CANCER, ISSN: 0007-0920
Sudaka A, Susini A, LoNigro C, Fischel J-L, Toussan N, Formento P, Tonissi F,
Occelli M, Merlano M, Milano G (2012).
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in
vivo preclinical study.
INVESTIGATIONAL NEW DRUGS, ISSN: 0167-6997
Garrone O, Crosetto N, LoNigro C, Catzeddu T, Vivenza D, Monteverde M,
Merlano M, Feola M (2012).
Prediction of antracycline cardiotoxicity after chemotherapy by biomarkers kinetic
analysis.
CARDIOVASCULAR TOXICOLOGY, ISSN: 1530-7905
Bracarda S, Ruggeri EM, Monti M, Merlano M, D'Angelo A, Ferraù F, Cortesi E,
Santoro A (2012).
Early detection, prevention and management of cutaneous adverse events due to
sorafenib:
Recomandations from the sorafenib Working Group.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, ISSN: 1040-8428
Merlano M, Monteverde M, Colantonio I, Denaro N, LoNigro C, Natoli G, Giurlasda
F, (...), Russi E (2012).
Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients
with head
and neck cancer.
ORAL ONCOLOGY, vol. 48, ISSN: 1368-8375
Guerin E, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC,
Formento P, Lattanzio L, Merlano M, (...), Milano G (2012).
Contrasted effects of the multitarget TKI vandetanib on docetaxel sensitive and
docetaxel resistant prostate cancer cell lines.
UROLOGIC ONCOLOGY, ISSN: 1078-1439
Russi EG, Corvò R, Merlotti A, Alterio D, Franco P, Pergolizzi S, De Sanctis V,
Merlano M, (...) Bernier J (2012).
Swallowing disfunction in head and neck cancer patients treated by radiotherapy:
Review and
recommendations of supportive task group of the Italian Association of Radiation
Oncology. CANCER TREATMENT REVIEWS, ISSN: 0305-7372
Wang H, Lee S, LoNigro C, Lattanzio L, Merlano M, Monteverde M, Matin R,
Occelli M, (...), Crook T (2012).
NT5E (CD 73) is epigenetically regulated in malignant melanoma and associated
with
metastatic site specificity.
LoNigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A,
Merlano M, (...) Crook T (2012).
High frequency of complex TP53 mutations in CNS metastases from breast cancer.
Russi EG, Merlano M, Numico G, Corvò R, Benasso M, Vigna-Taglianti R, Melano
A, (...) Ricardi U (2012).
The effects of pain and activity of the daily living caused by crusted exudation in
patients with
head and neck cancer treated with cetuximab and radiotherapy.
Pagina 7 -
SUPPORTIVE CARE IN CANCER, ISSN: 0941-4355
Guerin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, (...),
Merlano M, Milano G (2012).
Contrasted effects of the multitarget TKI vandetanib on docetaxel-sensitive and
docetaxel-resistant prostate cancer cell lines.
UROLOGIC ONCOLOGY, ISSN: 1078-1439
Hatzimichael, E., Lo Nigro, C., Lattanzio, L., Syed, N., Shah, R., Dasoula, A.,
Janczar, K., Vivenza, D., Monteverde, M., Merlano M, Papoudou-Bai, A., Bai, M.,
Schmid, P., Stebbing, J., Bower, M., Dyer, M.J.S., Karran, L.E., Elguetakarstegl,
C., Farrell, P.J., Thompson, A., Briasoulis, E., Crook, T. (2012).
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in
lymphoma. BRITISH JOURNAL OF CANCER, ISSN: 0007-0920
Lattanzio L, Tonissi F, Monteverde M, Milano G, Merlano M, Lo Nigro C. (2012).
Differential molecular mechanism of docetaxel-octreotide combined treatment
according to the docetaxel-resistance status in PC3 prostate cancer cells.
ANTI-CANCER DRUGS, ISSN: 1473-5741
Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC, IES
Trial Steering Committee, Merlano M (2012).
Long-term assessment of quality of life in the Intergroup Exemestane Study: 5
years post-randomisation.
Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ, IES Steering
Committee, Merlano M (2012).
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal
women with early
breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a
retrospective analysis of the Intergroup Exemestane Study.
LANCET ONCOLOGY, ISSN: 1470-2045
Numico G, Occelli M, Russi EG, Silvestris N, Pasero R, (....), Merlano M (2011).
Survival prediction and frequency of anticancer treatment in cancer patients
hospitalized due to acute conditions. Role of clinical parameters and PaP score.
SUPPORTIVE CARE IN CANCER, ISSN: 0941-4355
Bernier J, Russi EG, Homey B, Merlano M, Mesia R, Peyrade F, Budach W (2011).
Management of radiation dermatitis in patients receiving cetuximab and
radiotherapy for locally advanced squamous cell carcinoma of the head and neck:
proposal for a revised grading system and consensus management guidelines.
ANNALS OF ONCOLOGY, ISSN: 0923-7534
Denaro N, Russi EG, Adamo V, Colantonio I, Merlano M (2011).
Postoperative therapy in head and neck cancer: state of the art, risk subset,
prognosis and unsolved questions.
ONCOLOGY, ISSN:0030-2414
Feola M, Garrone O, Occelli m, Francini A, Biggi A, Visconti G, (...), Merlano M
(2011). Cardiotoxicity after anthracycline chemotherapy in breast carcinoma:
effects on left ventricular ejection fraction, troponin and brain natriuretic peptide.
INTERNATIONAL JOURNAL OF CARDIOLOGY, ISSN: 0167-5273
Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano M, Ferrais D, Maiello E
(2011). Management of skin toxicity associated with cetuximab treatment in
combination with chemotherapy or radiotherapy.
Pagina 8 -
THE ONCOLOGIST, ISSN: 1083-7159
Russi EG, Numico G, Merlano M, Pinto C (2011).
cetuximab related radiation dermatitis in head and neck cancer patients: in regard
to Suder et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS,
ISSN: 0360-3016
Merlano M, Russi EG, Benasso M, (...), Garrone O (2011).
Cisplatin based chemoradiation plus cetuximab in locally advanced head and neck
cancer: a phase II clinical study.
ANNALS OF ONCOLOGY, ISSN: 0923-7534
2011 - Contributo in volume (Capitolo o Saggio)
Locati L.D., Merlano M (2011).
Terapia medica integrata nei carcinomi squamocellulari. In: tumori della testa e del
collo. Springer Ed..
LoNigro C, Monteverde M, Riba M, Latanzio L Garrone O, (...), Merlano M (2010).
Expressione profiling and long lasting responses to chemotherapy in metastatic
gastric cancer.
INTERNATIONAL JOURNAL OF ONCOLOGY, ISSN: 1019-6439
Loupakis F, Masi G, Fornaro L, Vasile E (...), Merlano M, Falcone A (2010).
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV)
followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients
with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, ISSN: 0344-5704
Caponigro F, Lorusso D, Fornari G, Barone C, Merlano M, (...), Comis S (2010).
Phase I dose escalation study of brostallicin, a minor groove binder, in combination
with cisplatin in patients with advanced solid tumors.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, ISSN: 0344-5704
Numico G, Russi EG, Colantonio I, (...), Merlano M (2010).
EGFR status and prognosis of patients with locally advanced head and neck
cancer treated with chemoradiotherapy.
ANTICANCER RESEARCH, ISSN: 0250-7005
2010 - Contributo in volume (Capitolo o Saggio)
Merlano M, Garrone O (2010).
Tumori del distretto cervico-facciale. In: Oncologia Medica Pratica
Società Editrice Universo Ed..
UTORI, TITOLO, DOVE PUBBLICATO, QUANDO
Data di ultimo aggiornamento: 30/09/2015
Pagina 9 -

merlano marco carlo - Azienda Ospedaliera S. Croce e Carle

Transcript

Documenti analoghi

Rivista: Cose di Casa Data: settembre 2010 Frequenza

Spett.le Direzione della Rivista Argomenti OGGETTO: Liberatoria

Cv D`Alesio Maria - Accademia di Belle Arti di L`Aquila

Stampa - Chartabianca

Corso Sperimentazione Clinica in Azienda

Uscita in edicola venerdì 4 marzo

COMUNICATO La rivista KI, seppure organo non ufficiale della CIK

Giano bifronte o Master and commander ?

Fonte: Sole 24 ORE S.p.A. – Rivista: Mark Up Ritaglio stampa non